None
EN
Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide
[]
All Articles on Seeking Alpha
Protagonist Therapeutics ( PTGX ) stock had been on an upward trend for most of 2025.
That scientific foundation gave me an appreciation for the rigor and challenges behind drug development, which I now bring into my work as an investor and analyst.
I am not receiving compensation for it (other than from Seeking Alpha).
Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole.
Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.